Abses Otak/ Abses Serebri
Published on September 4, 2026
Risk Factors
Contiguous infection (sinusitis, otitis media, dental abscess), hematogenous spread (infective endocarditis, lung abscess, IV drug use), penetrating head trauma, post-neurosurgical procedures, immunocompromised states (HIV/AIDS, organ transplant, chronic steroid use)
Etiology
Polymicrobial in many cases. Streptococci (most common overall), Staphylococcus aureus (post-trauma, post-surgical), anaerobes (Bacteroides, Fusobacterium from dental/sinus source), Gram-negatives (Enterobacteriaceae from otogenic source). In immunocompromised: Toxoplasma gondii (HIV with CD4 < 100), Nocardia, Aspergillus, Mucor
Presentation
Headache is the most common symptom (>70% of cases). The classic triad of headache, fever, and focal neurologic deficit is present in fewer than half of patients. Nausea, vomiting, seizures, and altered mental status may also occur
Classic Exam
Papilledema, focal neurologic deficit (hemiparesis, aphasia depending on location), nuchal rigidity (if rupture into ventricle), altered level of consciousness
Diagnostics
CT head with contrast showing a ring-enhancing lesion with surrounding vasogenic edema. MRI with gadolinium is the most accurate imaging modality. Stereotactic needle aspiration provides definitive microbiologic diagnosis
Management
Empiric IV antibiotics: third-generation cephalosporin (ceftriaxone) + metronidazole. Add vancomycin if post-traumatic or post-surgical. Surgical aspiration or excision for abscesses > 2.5 cm. Total antibiotic duration: 6 to 8 weeks IV
KEYWORDS
"Ring-enhancing lesion," "contiguous spread from sinusitis," "dental infection with new headache and focal deficit," "immunocompromised with ring-enhancing lesion"
01Pathophysiology
Brain abscess develops through a predictable sequence that directly explains both the imaging findings and the clinical presentation.
Bacteria reach the brain parenchyma through three primary routes. Contiguous spread is the most common mechanism, where infection extends directly from an adjacent focus such as the paranasal sinuses, middle ear, or mastoid air cells through erosion of bone and dura. The frontal lobe is classically involved with sinusitis, while the temporal lobe and cerebellum are affected by otogenic infections. Hematogenous dissemination occurs when bacteremia seeds the brain, typically at the gray-white matter junction where blood flow slows in small-caliber end arterioles. This route tends to produce multiple abscesses and is associated with endocarditis, pulmonary arteriovenous malformations (as in hereditary hemorrhagic telangiectasia), and right-to-left cardiac shunts that bypass the pulmonary capillary filter. Direct inoculation occurs after penetrating trauma or neurosurgical procedures.
Once organisms establish in brain tissue, the abscess evolves through four histopathological stages. Early cerebritis (days 1 to 3) features a poorly demarcated area of neutrophilic infiltration and edema. Late cerebritis (days 4 to 9) shows central necrosis with a developing inflammatory rim. Early capsule formation (days 10 to 13) is when fibroblasts and neovascularization lay down a collagen capsule, and this is the stage at which the classic ring-enhancing pattern appears on contrast imaging. Late capsule (day 14 onward) is a well-formed, thick collagen wall encasing the purulent core.
The clinical symptoms follow logically from this process. The expanding mass and surrounding vasogenic edema create a local mass effect, which produces focal neurologic deficits corresponding to the involved region. Rising intracranial pressure causes the progressive headache, nausea, vomiting, and papilledema. Fever results from the systemic inflammatory response, although it is notably absent in up to 50% of patients, making the classic triad an unreliable screening criterion. Seizures occur because the inflammatory process irritates adjacent cortical neurons. If the abscess ruptures into the ventricular system (intraventricular rupture), the patient deteriorates rapidly with sudden meningismus, obtundation, and a sharp increase in mortality.
02Classification and Clinical Manifestation
Classification by Source of Infection
Paranasal sinusitis (frontal, ethmoid)
TYPICAL ORGANISM(S)
Streptococci, anaerobes, Haemophilus
USUAL ABSCESS LOCATION
Frontal lobe
Otitis media / mastoiditis
TYPICAL ORGANISM(S)
Streptococci, Bacteroides, Enterobacteriaceae
USUAL ABSCESS LOCATION
Temporal lobe, cerebellum
Dental infection
TYPICAL ORGANISM(S)
Mixed anaerobes (Fusobacterium, Prevotella, Actinomyces)
USUAL ABSCESS LOCATION
Frontal lobe
Hematogenous (endocarditis, lung abscess)
TYPICAL ORGANISM(S)
Streptococcus viridans, Staphylococcus aureus
USUAL ABSCESS LOCATION
Multiple lesions at gray-white junction
Penetrating trauma / post-surgical
TYPICAL ORGANISM(S)
Staphylococcus aureus, Enterobacteriaceae
USUAL ABSCESS LOCATION
At the site of injury
HIV/AIDS (CD4 < 100)
TYPICAL ORGANISM(S)
Toxoplasma gondii
USUAL ABSCESS LOCATION
Basal ganglia (bilateral, multiple)
Transplant / neutropenia
TYPICAL ORGANISM(S)
Aspergillus, Nocardia, Mucor
USUAL ABSCESS LOCATION
Variable; often multiple
SOURCE | TYPICAL ORGANISM(S) | USUAL ABSCESS LOCATION |
|---|---|---|
Paranasal sinusitis (frontal, ethmoid) | Streptococci, anaerobes, Haemophilus | Frontal lobe |
Otitis media / mastoiditis | Streptococci, Bacteroides, Enterobacteriaceae | Temporal lobe, cerebellum |
Dental infection | Mixed anaerobes (Fusobacterium, Prevotella, Actinomyces) | Frontal lobe |
Hematogenous (endocarditis, lung abscess) | Streptococcus viridans, Staphylococcus aureus | Multiple lesions at gray-white junction |
Penetrating trauma / post-surgical | Staphylococcus aureus, Enterobacteriaceae | At the site of injury |
HIV/AIDS (CD4 < 100) | Toxoplasma gondii | Basal ganglia (bilateral, multiple) |
Transplant / neutropenia | Aspergillus, Nocardia, Mucor | Variable; often multiple |
Clinical Manifestation by Abscess Location
LOCATION | EXPECTED CLINICAL FINDINGS |
|---|---|
Frontal lobe | Personality change, abulia, expressive aphasia (dominant hemisphere), contralateral hemiparesis, seizures |
Temporal lobe | Receptive aphasia (dominant side), contralateral superior quadrantanopia, behavioral changes |
Cerebellum | Ataxia, nystagmus, dysmetria, headache with vomiting (risk of obstructive hydrocephalus) |
Parietal lobe | Hemisensory loss, visual field cut, spatial neglect (non-dominant) |
Brainstem | Cranial nerve palsies, contralateral hemiparesis, altered consciousness (rare, high mortality) |
03Diagnostic Workup
CT head with IV contrast
ROLE
Best initial test
KEY FINDING
Hypodense center with a uniform, thin ring of contrast enhancement and surrounding hypodense edema
MRI brain with gadolinium
ROLE
Most accurate test
KEY FINDING
Ring-enhancing lesion with restricted diffusion (bright on DWI, dark on ADC map) in the abscess cavity
DWI/ADC on MRI
ROLE
Distinguishes abscess from tumor
KEY FINDING
Abscess shows restricted diffusion (bright DWI, dark ADC); tumor necrosis does not
Stereotactic needle aspiration
ROLE
Gold standard for microbiologic diagnosis
KEY FINDING
Culture and sensitivity of aspirated pus; also therapeutic (decompression)
Blood cultures
ROLE
Identify hematogenous source
KEY FINDING
Positive in approximately 25 to 30% of cases
CBC, ESR, CRP
ROLE
Supportive, nondiagnostic
KEY FINDING
Leukocytosis (variable), elevated inflammatory markers
Lumbar puncture
ROLE
Contraindicated in most cases
KEY FINDING
Risk of transtentorial herniation due to mass effect
TEST | ROLE | KEY FINDING |
|---|---|---|
CT head with IV contrast | Best initial test | Hypodense center with a uniform, thin ring of contrast enhancement and surrounding hypodense edema |
MRI brain with gadolinium | Most accurate test | Ring-enhancing lesion with restricted diffusion (bright on DWI, dark on ADC map) in the abscess cavity |
DWI/ADC on MRI | Distinguishes abscess from tumor | Abscess shows restricted diffusion (bright DWI, dark ADC); tumor necrosis does not |
Stereotactic needle aspiration | Gold standard for microbiologic diagnosis | Culture and sensitivity of aspirated pus; also therapeutic (decompression) |
Blood cultures | Identify hematogenous source | Positive in approximately 25 to 30% of cases |
CBC, ESR, CRP | Supportive, nondiagnostic | Leukocytosis (variable), elevated inflammatory markers |
Lumbar puncture | Contraindicated in most cases | Risk of transtentorial herniation due to mass effect |
When a patient presents with headache, fever, and focal neurologic deficit, the immediate next step is a CT head with IV contrast. This is the best initial test because it is widely available, fast, and reliably demonstrates the ring-enhancing lesion with surrounding edema. CT also helps rule out other emergencies such as hemorrhage.
If CT raises suspicion for abscess, MRI with gadolinium and diffusion-weighted imaging (DWI) is obtained next. MRI is the most accurate imaging study for brain abscess. The critical feature is restricted diffusion within the cavity: the pus in an abscess restricts water movement, producing a bright signal on DWI and a corresponding dark signal on the ADC map. This is a high-yield discriminator because necrotic tumors (like glioblastoma) also ring-enhance but typically do NOT restrict diffusion. This single imaging feature is the most tested way to differentiate abscess from tumor on exam questions.
Stereotactic needle aspiration is both diagnostic and therapeutic. It provides material for Gram stain and culture to guide targeted antibiotic therapy, and it simultaneously drains the abscess. It is performed when the abscess is larger than 2.5 cm, when there is no clinical improvement after 1 to 2 weeks of empiric antibiotics, or when the diagnosis is uncertain.
A critical exam point: lumbar puncture is contraindicated when imaging shows a space-occupying lesion with mass effect. Removing CSF from below a supratentorial mass can precipitate uncal herniation. If a vignette describes a patient with a ring-enhancing lesion and asks for the next step, choosing lumbar puncture is a classic wrong answer.
Blood cultures should be obtained in all patients, as they are positive in roughly a quarter of cases and help identify the source of hematogenous spread. However, they should never delay neuroimaging.
04Management and Treatment
Empiric therapy (unknown source or contiguous spread)
REGIMEN
Ceftriaxone + Metronidazole
DOSE AND DURATION
Ceftriaxone 2 g IV every 12 hours + Metronidazole 500 mg IV every 8 hours; total 6 to 8 weeks
Post-traumatic or post-surgical
REGIMEN
Vancomycin + Ceftriaxone (or cefepime) + Metronidazole
DOSE AND DURATION
Vancomycin 15 to 20 mg/kg IV every 8 to 12 hours (target trough 15 to 20 mcg/mL) + Ceftriaxone 2 g IV every 12 hours + Metronidazole 500 mg IV every 8 hours; 6 to 8 weeks
HIV/AIDS with ring-enhancing lesion (presumed Toxoplasmosis)
REGIMEN
Pyrimethamine + Sulfadiazine + Leucovorin
DOSE AND DURATION
Pyrimethamine 200 mg loading then 50 to 75 mg/day + Sulfadiazine 1 to 1.5 g every 6 hours + Leucovorin 10 to 25 mg/day; minimum 6 weeks, then secondary prophylaxis until immune reconstitution
Nocardia (transplant patients)
REGIMEN
TMP-SMX (trimethoprim-sulfamethoxazole)
DOSE AND DURATION
TMP 15 mg/kg/day IV divided every 6 to 8 hours; 6 to 12 months total
Aspergillus (neutropenic, transplant)
REGIMEN
Voriconazole
DOSE AND DURATION
6 mg/kg IV every 12 hours x 2 doses (loading), then 4 mg/kg IV every 12 hours; duration guided by clinical response
Abscess > 2.5 cm or clinical deterioration
REGIMEN
Surgical aspiration or excision
DOSE AND DURATION
CT-guided stereotactic aspiration or open craniotomy with excision
Perilesional edema with mass effect
REGIMEN
Dexamethasone (adjunctive)
DOSE AND DURATION
4 to 10 mg IV every 6 hours; taper over days once edema improves. Use only when cerebral edema causes significant neurologic compromise
Seizures
REGIMEN
Antiepileptic (levetiracetam preferred)
DOSE AND DURATION
Levetiracetam 500 to 1000 mg IV/PO every 12 hours; duration depends on seizure recurrence risk
CLINICAL SCENARIO | REGIMEN | DOSE AND DURATION |
|---|---|---|
Empiric therapy (unknown source or contiguous spread) | Ceftriaxone + Metronidazole | Ceftriaxone 2 g IV every 12 hours + Metronidazole 500 mg IV every 8 hours; total 6 to 8 weeks |
Post-traumatic or post-surgical | Vancomycin + Ceftriaxone (or cefepime) + Metronidazole | Vancomycin 15 to 20 mg/kg IV every 8 to 12 hours (target trough 15 to 20 mcg/mL) + Ceftriaxone 2 g IV every 12 hours + Metronidazole 500 mg IV every 8 hours; 6 to 8 weeks |
HIV/AIDS with ring-enhancing lesion (presumed Toxoplasmosis) | Pyrimethamine + Sulfadiazine + Leucovorin | Pyrimethamine 200 mg loading then 50 to 75 mg/day + Sulfadiazine 1 to 1.5 g every 6 hours + Leucovorin 10 to 25 mg/day; minimum 6 weeks, then secondary prophylaxis until immune reconstitution |
Nocardia (transplant patients) | TMP-SMX (trimethoprim-sulfamethoxazole) | TMP 15 mg/kg/day IV divided every 6 to 8 hours; 6 to 12 months total |
Aspergillus (neutropenic, transplant) | Voriconazole | 6 mg/kg IV every 12 hours x 2 doses (loading), then 4 mg/kg IV every 12 hours; duration guided by clinical response |
Abscess > 2.5 cm or clinical deterioration | Surgical aspiration or excision | CT-guided stereotactic aspiration or open craniotomy with excision |
Perilesional edema with mass effect | Dexamethasone (adjunctive) | 4 to 10 mg IV every 6 hours; taper over days once edema improves. Use only when cerebral edema causes significant neurologic compromise |
Seizures | Antiepileptic (levetiracetam preferred) | Levetiracetam 500 to 1000 mg IV/PO every 12 hours; duration depends on seizure recurrence risk |
Acute stabilization begins with hemodynamic support and airway protection if consciousness is impaired. The "next best step" after imaging confirms a ring-enhancing lesion is to start empiric IV antibiotics immediately while arranging for surgical aspiration. Do not delay antibiotics waiting for culture results. Empiric therapy with a third-generation cephalosporin plus metronidazole provides coverage against streptococci, gram-negatives, and anaerobes, which reflects the most likely organisms from contiguous spread. Add vancomycin when trauma or surgery is part of the history, to cover methicillin-resistant Staphylococcus aureus.
Surgical intervention is indicated when the abscess diameter exceeds 2.5 cm, when there is significant mass effect or neurologic deterioration, when the abscess is located in the posterior fossa (risk of acute hydrocephalus), or when empiric antibiotics fail to produce clinical improvement within 1 to 2 weeks. Stereotactic aspiration is preferred over open excision for deep-seated or eloquent-area lesions. Open excision is reserved for multiloculated abscesses, fungal abscesses with thick capsules, or post-traumatic abscesses containing foreign material.
Dexamethasone is used cautiously. Steroids reduce perilesional edema and can rapidly improve neurologic status, but they also decrease antibiotic penetration into the abscess cavity and may impair capsule formation. For this reason, steroids are reserved for patients with significant mass effect causing impending herniation, not given routinely.
Long-term management consists of completing a full 6 to 8 weeks of IV antibiotics, guided by culture and sensitivity results once aspiration is performed. Serial CT or MRI imaging is obtained every 1 to 2 weeks to monitor abscess size and resolution. After completing IV therapy, some patients transition to oral antibiotics for an additional 2 to 3 months, depending on clinical response. Seizure prophylaxis may be continued for 3 to 6 months if the patient presented with seizures.
In the context of HIV/AIDS with multiple ring-enhancing lesions, the standard approach is an empiric trial of anti-Toxoplasma therapy (pyrimethamine, sulfadiazine, leucovorin) for 2 weeks. If the lesions do not shrink on follow-up imaging, stereotactic biopsy is performed to rule out primary CNS lymphoma.
05Differential Diagnosis and Distractors
Glioblastoma multiforme (GBM)
WHY IT IS SIMILAR
Ring-enhancing lesion on contrast CT/MRI with surrounding edema; can present with headache and focal deficit
KEY DISCRIMINATOR
GBM shows an irregular, thick, heterogeneous ring and does NOT restrict diffusion on DWI (bright DWI/dark ADC is abscess). No fever. Older patient without infectious risk factors. Biopsy is definitive
CNS Toxoplasmosis
WHY IT IS SIMILAR
Ring-enhancing lesions in an immunocompromised patient; fever and focal deficits
KEY DISCRIMINATOR
Multiple lesions with predilection for the basal ganglia in a patient with HIV and CD4 < 100. Positive Toxoplasma IgG serology. Empiric trial of anti-Toxoplasma therapy causes improvement within 2 weeks
Primary CNS Lymphoma
WHY IT IS SIMILAR
Ring-enhancing or homogeneously enhancing lesion in HIV; can look like abscess on imaging
KEY DISCRIMINATOR
Tends to be periventricular, solitary, homogeneously enhancing (not ring). Associated with EBV; CSF positive for EBV DNA by PCR. Does NOT improve with anti-Toxoplasma trial
Neurocysticercosis
WHY IT IS SIMILAR
Ring-enhancing or cystic lesions, seizures, headache
KEY DISCRIMINATOR
History of travel to or residence in an endemic area (Latin America, Southeast Asia). Imaging shows a cyst with a scolex (eccentric dot within the cyst). Serology (EITB) confirms
Tuberculoma
WHY IT IS SIMILAR
Ring-enhancing lesion in a patient from an endemic region; headache, focal deficits, fever
KEY DISCRIMINATOR
Often multiple lesions in the posterior fossa or basal region. Associated findings of pulmonary TB or basilar meningitis. Positive PPD/IGRA, CSF with lymphocytic pleocytosis, low glucose, high protein
Metastatic brain tumor
WHY IT IS SIMILAR
Multiple ring-enhancing lesions with edema
KEY DISCRIMINATOR
Known primary malignancy (lung, breast, melanoma). Lesions at the gray-white junction but no restricted diffusion, no fever, no infectious risk factors
Subdural empyema
WHY IT IS SIMILAR
Fever, headache, focal deficits, and a collection adjacent to the brain
KEY DISCRIMINATOR
Collection is crescent-shaped and extra-axial (between dura and arachnoid), not intraparenchymal. Often follows sinusitis or otitis. Rapidly progressive
DIFFERENTIAL | WHY IT IS SIMILAR | KEY DISCRIMINATOR |
|---|---|---|
Glioblastoma multiforme (GBM) | Ring-enhancing lesion on contrast CT/MRI with surrounding edema; can present with headache and focal deficit | GBM shows an irregular, thick, heterogeneous ring and does NOT restrict diffusion on DWI (bright DWI/dark ADC is abscess). No fever. Older patient without infectious risk factors. Biopsy is definitive |
CNS Toxoplasmosis | Ring-enhancing lesions in an immunocompromised patient; fever and focal deficits | Multiple lesions with predilection for the basal ganglia in a patient with HIV and CD4 < 100. Positive Toxoplasma IgG serology. Empiric trial of anti-Toxoplasma therapy causes improvement within 2 weeks |
Primary CNS Lymphoma | Ring-enhancing or homogeneously enhancing lesion in HIV; can look like abscess on imaging | Tends to be periventricular, solitary, homogeneously enhancing (not ring). Associated with EBV; CSF positive for EBV DNA by PCR. Does NOT improve with anti-Toxoplasma trial |
Neurocysticercosis | Ring-enhancing or cystic lesions, seizures, headache | History of travel to or residence in an endemic area (Latin America, Southeast Asia). Imaging shows a cyst with a scolex (eccentric dot within the cyst). Serology (EITB) confirms |
Tuberculoma | Ring-enhancing lesion in a patient from an endemic region; headache, focal deficits, fever | Often multiple lesions in the posterior fossa or basal region. Associated findings of pulmonary TB or basilar meningitis. Positive PPD/IGRA, CSF with lymphocytic pleocytosis, low glucose, high protein |
Metastatic brain tumor | Multiple ring-enhancing lesions with edema | Known primary malignancy (lung, breast, melanoma). Lesions at the gray-white junction but no restricted diffusion, no fever, no infectious risk factors |
Subdural empyema | Fever, headache, focal deficits, and a collection adjacent to the brain | Collection is crescent-shaped and extra-axial (between dura and arachnoid), not intraparenchymal. Often follows sinusitis or otitis. Rapidly progressive |
06Traps and High-Yield Pearls
The single most common way students lose points on brain abscess questions is by selecting lumbar puncture as the next step in a patient with a ring-enhancing lesion. Once imaging reveals a space-occupying lesion with surrounding edema, LP is contraindicated due to the risk of herniation. This is tested repeatedly and is designed to punish reflexive thinking (fever plus headache equals meningitis workup).
A second frequent trap involves distinguishing brain abscess from a necrotic glioblastoma. Both produce ring-enhancing lesions. The vignette will often contain the critical clue in the DWI/ADC findings: restricted diffusion (bright DWI, dark ADC) within the lesion cavity points to abscess, while a tumor cavity typically shows facilitated diffusion. If the question stem does not provide diffusion data, look instead for infectious risk factors (recent sinusitis, dental procedure, endocarditis, IV drug use) versus cancer risk factors (older age, weight loss, smoking history).
In HIV patients, a ring-enhancing lesion defaults to Toxoplasma gondii until proven otherwise. The tested management principle here is the empiric anti-Toxoplasma trial: treat for 2 weeks, then reimage. If the lesions shrink, the diagnosis is confirmed. If they do not, the next step is biopsy to evaluate for CNS lymphoma. Do not biopsy first in this scenario unless there is a solitary periventricular lesion or negative Toxoplasma IgG, which would make lymphoma more likely from the outset.
Finally, remember that the classic triad (headache, fever, focal deficit) is present in fewer than 50% of patients. A vignette may present an afebrile patient with only a persistent headache and a subtle neurologic finding. The core competency being tested is the ability to maintain a high index of suspicion for abscess in any patient with a subacute headache and a predisposing condition, even when the full triad is absent.